Patents Examined by Titilayo Moloye
  • Patent number: 12043836
    Abstract: The present invention provides cell lines for high efficiency genome editing using cas/CRISPR systems, methods of generating such cells lines and methods of generating mutations in the genome of an organism using such cell lines.
    Type: Grant
    Filed: September 30, 2020
    Date of Patent: July 23, 2024
    Assignee: Viridos, Inc.
    Inventors: John Verruto, Eric Moellering
  • Patent number: 12024717
    Abstract: According to the present invention, there are provided a method for producing a human T cell, which comprises the steps of inducing an iPS cell from a human T cell, and differentiating the iPS cell into a T cell; a pharmaceutical composition comprising the T cell produced by the method; and a method for cell-based immunotherapy using the method.
    Type: Grant
    Filed: August 12, 2020
    Date of Patent: July 2, 2024
    Assignee: The University of Tokyo
    Inventors: Hiromitsu Nakauchi, Shin Kaneko, Toshinobu Nishimura
  • Patent number: 12018274
    Abstract: The present disclosure relates to one or more agents, therapies, treatments, and methods of use of the agents and/or therapies and/or treatments for increasing production of a belatacept-similar protein and micro-RNA associated with decreasing production of tumor necrosis factor alpha. Embodiments of the present disclosure can be used as a therapy or a treatment for a subject that has a condition whereby the subject's immune system is, or is likely to become, dysregulated and where the production of the belatacept-similar protein and decreased production of tumor necrosis factor alpha may be of therapeutic benefit.
    Type: Grant
    Filed: July 19, 2022
    Date of Patent: June 25, 2024
    Assignee: Wyvern Pharmaceuticals Inc.
    Inventor: Bradley G. Thompson
  • Patent number: 12018281
    Abstract: The present invention provides a cardiomyocyte maturation promoter. The present invention provides a cardiomyocyte maturation promoter comprising one or more compounds selected from 2-methoxy-5-((Z)-2-(3,4,5-trimethoxyphenyl)vinyl)phenol, (1-ethyl-1H-benzotriazol-5-yl)methyl (2-(2-methoxy-4-methylphenyl)-4-methyl-1,3-thiazol-5-yl)carbamate, (2?beta)-22-oxovincaleukoblastine, 2-(2-(4-chlorophenyl)ethyl)-6-(2-furyl)-3H-imidazo[4,5-b]pyridine, 4,5-anhydro-1,2-dideoxy-4-methyl-2-((N-(morpholin-4-ylacetyl)-L-alanyl-O-methyl-L-tyrosyl)amino)-1-phenyl-L-threo-pent-3-ulose, 3-(3-methoxyphenyl)-N7,N7-dimethylisoquinoline-1,7-diamine, methyl 4-(2-benzylbenzoyl)-2,5-dimethyl-1H-pyrrole-3-carboxylate, 2?-(4-aminophenyl)-1H,1?H-2,5?-bibenzimidazol-5-amine, and salts thereof.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: June 25, 2024
    Assignees: Kyoto University, Takeda Pharmaceutical Company Limited
    Inventors: Yoshinori Yoshida, Kenji Miki, Shigeru Kondo
  • Patent number: 11987808
    Abstract: The present invention relates to the field of stem cell biology, in particular the linage specific differentiation of pluripotent or multipotent stem cells. Specifically described are methods to direct the lineage specific differentiation of hiPSC to sensitive neurons or neuronal fibers innervating the human skin, such as neural crest stem cells (NCPCs) and here called peripheral sensory neurons (PSNs) using novel culture conditions. It is also described a method for screening a biological agent in vitro. The PSNs obtained using the methods of the present invention are further contemplated for various uses including, but limited to, use in in vitro tests or disease modelling, such as drug discovery assays, cell therapy on a higher scale, detecting a range of skin irritants and other compounds of interest, for studying skin aging mechanism, and for producing a dermocosmetic product.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: May 21, 2024
    Assignee: L'OREAL
    Inventors: Rodrigo De Vecchi, Stevens Kastrup Rehen, Marilia Zaluar, Lionel Breton
  • Patent number: 11980642
    Abstract: The present invention relates to a method of inducing differentiation into a 3D dopaminergic midbrain organoid using a specific electromagnetic wave. It was specifically identified that the method makes it possible to remarkably improve production efficiency of a dopaminergic neuronal 3D-differentiated organoid, from which symptoms of Parkinson's disease can be effectively alleviated. Thus, it is anticipated that the present invention is capable of making a more fundamental approach and achieving targeted therapies in the treatment of a cranial nerve disease.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: May 14, 2024
    Inventors: Jongpil Kim, Junsang Yoo
  • Patent number: 11981931
    Abstract: The invention generally features compositions comprising induced pluripotent stem cell progenitors (also termed reprogramming progenitor cells) and methods of isolating such cells. The invention also provides compositions comprising induced pluripotent stem cells (iPSCs) derived from such progenitor cells. Induced pluripotent stem cell progenitors generate iPSCs at high efficiency.
    Type: Grant
    Filed: December 8, 2020
    Date of Patent: May 14, 2024
    Assignee: Salk Institute for Biological Studies
    Inventors: Ronald Evans, Michael Downes, Yasuyuki Kida, Teruhisa Kawamura, Zong Wei, Ruth T. Yu, Annette R. Atkins
  • Patent number: 11959095
    Abstract: An extrudable hydrogel composition useful for making a three-dimensional organ construct is described herein. Methods of using the same and products so made are also described. Also described herein is a multicellular organoid including at least two tumor cells or cell lines that are of the same tissue type, but are distinct from one another (e.g., distinct in morphology, growth rate, and/or at least one mutation); and at least one type of non-cancerous (i.e., normal or differentiated) tissue cells, wherein the at least one type of non-cancerous tissue cells are of the same tissue type as the at least two tumor cells or cell lines. In some embodiments, the at least two tumor cells or cell lines and/or the non-cancerous tissue cells are labeled with and/or comprise a detectable compound, optionally so that each of the different cells can be distinguished from each other (e.g., optically and/or electrically distinguished).
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: April 16, 2024
    Assignee: Wake Forest University Health Sciences
    Inventors: Aleksander Skardal, HemaMylammal Salem Muthu Sugavanam Sivakumar
  • Patent number: 11959098
    Abstract: Provided is an isolated population of human pluripotent stem cells comprising at least 50% human pluripotent stem cells characterized by an OCT4+/TRA1-60?/TRA1-81?/SSEA1+/SSEA4? expression signature, and novel methods of generating and maintaining same in a pluripotent, undifferentiated state a suspension culture devoid of cell clumps. Also provided are novel culture media, cell cultures and methods for culturing pluripotent stem cells in a suspension culture or a two-dimensional culture system while maintaining the cells in a proliferative, pluripotent and undifferentiated state. The novel culture media comprise interleukin 11 (IL11) and Ciliay Neurotrophic Factor (CNTF); bFGF at a concentration of at least 50 ng/ml and an IL6RIL6 chimera; or an animal contaminant-free serum replacement and an IL6RIL6 chimera. Also provided are methods for generating lineage-specific cells from the pluripotent stem cells.
    Type: Grant
    Filed: March 5, 2020
    Date of Patent: April 16, 2024
    Assignee: Technion Research & Development Foundation Limited
    Inventors: Michal Amit, Joseph Itskovitz-Eldor
  • Patent number: 11950578
    Abstract: Mice are provided that comprise a reduction or deletion of ADAM6 activity from an endogenous ADAM6 locus, or that lack an endogenous locus encoding a mouse ADAM6 protein, wherein the mice comprise a sequence encoding an ADAM6 or ortholog or homolog or fragment thereof that is functional in a male mouse. In one embodiment, the sequence is an ectopic ADAM6 sequence or a sequence that confers upon a male mouse the ability to generate offspring by mating. Mice and cells with genetically modified immunoglobulin heavy chain loci that comprise an ectopic nucleotide sequence encoding a mouse ADAM6 or functional fragment or homolog or ortholog thereof are also provided.
    Type: Grant
    Filed: December 21, 2020
    Date of Patent: April 9, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Sean Stevens, Andrew J. Murphy, Margaret Karow
  • Patent number: 11937586
    Abstract: Methods, compositions and non-human animals and parts thereof are for improving germ line transmission of genetic modifications. The methods and compositions are for producing non-human embryos with a disrupted or disruptable fertility gene. The embryos can be used as hosts for the development of donor pluripotent cells, including genetically modified donor pluripotent cells, into germ cells and gametes. Additional methods and compositions are for producing from such embryos chimeric non-human animals with a disrupted fertility gene and for breeding the chimeric non-human animals with cognate non-human animals that comprise a fertility gene that lacks a disruption to produce non-human animals having substantially all gametes and/or germ cells derived from the donor pluripotent cells. Non-human gametes, germ cells, embryos and animals can be used in the subject methods.
    Type: Grant
    Filed: November 30, 2021
    Date of Patent: March 26, 2024
    Inventor: Frank Koentgen
  • Patent number: 11926842
    Abstract: In some aspects, the disclosure provides recombinant AAV and nucleic acid constructs having novel inverted terminal repeats (ITRs), cap, and/or rep genes. In some aspects, the disclosure relates to gene transfer methods using rAAVs described herein.
    Type: Grant
    Filed: February 1, 2022
    Date of Patent: March 12, 2024
    Assignee: University of Massachusetts
    Inventors: Guangping Gao, Phillip Tai, Elisabet C. Mandon, Jianzhong Ai
  • Patent number: 11926849
    Abstract: Ex vivo monolayer models of human interstinal epithelia that express sensors, and methods of use thereof for evaluation of the effects of test compounds on the human gut.
    Type: Grant
    Filed: March 30, 2020
    Date of Patent: March 12, 2024
    Assignees: The General Hospital Corporation, Massachusetts Institute Of Technology
    Inventors: Alessio Fasano, Timothy K. Lu, Stefania Senger, Maria Eugenia Inda
  • Patent number: 11920154
    Abstract: The present invention provides compositions and methods for the culture and maintenance of pluripotent stem cells. More particularly, the present invention provides for compositions and methods for culturing, maintaining, growing and stabilizing primate pluripotent stem cells in a feeder-free defined media further comprising human serum, or a soluble attachment component of the human serum, for promoting cell attachment.
    Type: Grant
    Filed: October 19, 2020
    Date of Patent: March 5, 2024
    Assignee: ViaCyte, Inc.
    Inventors: Allan J Robins, Thomas C Schulz
  • Patent number: 11912823
    Abstract: Provided herein are methods of preparing a poloxamer for use in a cell culture medium. Also provided herein are cell culture media containing the poloxamer prepared by the methods herein, as well as methods of using the media for cell culturing and polypeptide production from cells.
    Type: Grant
    Filed: May 13, 2021
    Date of Patent: February 27, 2024
    Assignee: Genentech, Inc.
    Inventors: Ganesh Prasadh Vissvesvaran, Robert David Kiss, Steven J. Meier, Inchan Kwon, Kara Calhoun, Kate Winchester, Amelia Adams, Marion Glenn, Stefan Koenig, Alan Deese
  • Patent number: 11896614
    Abstract: The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), compositions and reaction mixtures comprising the same, and methods of treatment using the same.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: February 13, 2024
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: David M. Barrett, Felipe Bedoya, Saba Ghassemi, Carl H. June, Bruce L. Levine, Jan J. Melenhorst, Michael C. Milone, Daniel J. Powell, Jr., Nathan Amar Singh, Zoe Zheng
  • Patent number: 11898169
    Abstract: Disclosed herein are methods of generating induced pluripotent stem cells. The method involves providing a quantity of somatic or non-embryonic cells, contacting the contacting the somatic or non-embryonic cells with a quantity of one or more programming factors and one or more RNA molecules, and culturing the somatic or non-embryonic cells for a period of time sufficient to generate at least one induced pluripotent stem cell. Various reprogramming factors and RNA molecules for use in the methods are disclosed herein. Also disclosed are cell lines and pharmaceutical compositions generated by use of the methods.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: February 13, 2024
    Assignee: The McLean Hospital Corporation
    Inventors: Kwang-Soo Kim, Young Cha
  • Patent number: 11840708
    Abstract: A method of creating an isogenic multicellular blood-brain barrier model from iPSCs is disclosed.
    Type: Grant
    Filed: April 4, 2017
    Date of Patent: December 12, 2023
    Inventors: Eric V. Shusta, Scott G. Canfield, Clive N. Svendsen, Sean P. Palecek, Gad D. Vatine
  • Patent number: 11833367
    Abstract: Methods of treating a subject are provided, involving providing a first region of biological material coupled to the subject; initiating a change in a cellular environment of the cells in the first region; and due to a change in biological or chemical activity of the cells in the first region, inducing a biological change in a second region inside the subject, along with various biophoton collectors and biophoton bypasses useful for implementing a variety of the method embodiments.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: December 5, 2023
    Inventors: Frederic A. Bourke, Jr., Harold Walder, Zakaryae Fathi, Wayne F. Beyer, Jr., Ronald A. Rudder
  • Patent number: 11825820
    Abstract: A knock-in non-human mammal comprising a recombinant androgen receptor (AR) cassette containing an exogenous human polyglutamine (polyQ) tract encoding sequence in exon 1, wherein the human polyQ tract encoding sequence is stably integrated into the genome of the animal. Also provided are recombinant cells, fertilized eggs and tissues. The resulting animal displays a wide range of phenotypes, best characterized as Metabolic Syndrome and can be used in screening and other assays.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: November 28, 2023
    Inventors: Mark Trifiro, Miltiadis Paliouras, Lenore K. Beitel, Carlos Alvarado